RHHBY Announces Encouraging Phase III Results for Breast Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy LLY?
Source: NASDAQ.COM
Positive Study Results: Roche's giredestrant showed significant benefits in the lidERA Breast Cancer study, outperforming standard endocrine therapy in invasive disease-free survival for patients with ER-positive, HER2-negative breast cancer.
Market Impact: The success of giredestrant is expected to enhance Roche's breast cancer portfolio, which includes established drugs like Herceptin and Kadcyla, amidst increasing competition from biosimilars.
Ongoing Development: Roche is conducting extensive clinical trials for giredestrant across various treatment settings, indicating a strong commitment to advancing its breast cancer treatment options.
Competitive Landscape: Eli Lilly's recent approval of imlunestrant for advanced breast cancer adds to the competitive environment, highlighting the ongoing innovation in treatments for ER-positive breast cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1020.840
Low
950.00
Averages
1192
High
1500
Current: 1020.840
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Strong Q4 Results Driven by Weight-Loss Drugs
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs generated $7.4 billion in Q4 sales, a 110% increase, while Zepbound's revenue surged from $1.9 billion to $4.3 billion, indicating strong market demand and product acceptance.
- Overall Performance Exceeds Expectations: The company reported a 43% increase in total revenue to $19.29 billion for Q4, with adjusted earnings per share (EPS) jumping 42% to $7.54, significantly surpassing analyst expectations of $6.67, reflecting the company's competitive edge and profitability.
- Optimistic Future Outlook: Eli Lilly projects 2026 revenue between $80 billion and $83 billion, representing a 25% growth at the midpoint, and forecasts adjusted EPS ranging from $33.50 to $35, demonstrating confidence in future market demand.
- Huge Potential for New Drug: The upcoming oral GLP-1 drug orforglipron is expected to gain approval in Q2, and its convenient administration method positions Eli Lilly to further expand its market share in the GLP-1 drug sector, reinforcing the company's leadership in weight-loss medications.
See More
Novo Nordisk Sues Hims Over Patent Infringement
- Escalating Legal Action: Novo Nordisk has filed a lawsuit seeking a permanent ban on Hims from selling compounded drugs that infringe its patents while also pursuing damages, demonstrating its commitment to defending its interests in the rapidly growing obesity drug market.
- Intensified Market Competition: Hims planned to offer its newly launched obesity pill at $49 per month, significantly lower than Novo's Wegovy, but has decided to halt sales after facing scrutiny from regulators and legal threats from the Danish drugmaker.
- Patient Safety Concerns: Novo accused Hims of deceiving patients by marketing unapproved drugs that lack FDA verification, highlighting the critical importance of regulatory standards to ensure drug safety and efficacy.
- FDA Investigation: The FDA has announced plans to take legal action against Hims, including restricting access to drug ingredients and referring the company to the Department of Justice for potential violations, further complicating Hims' legal challenges.
See More
Wall Street Futures Steady as Investors Await Economic Data
- Tech Stock Decline: Concerns over AI have led to a decline in tech stocks over the past week, putting pressure on the market as investors await crucial economic data and hints from the Federal Reserve regarding potential rate cuts.
- Dow Jones Performance: The Dow Jones closed above 50,000 points for the first time on Friday, posting significant weekly gains, indicating a rotation of funds into other sectors and boosting investor confidence.
- Economic Data Focus: Key economic releases, including the nonfarm payrolls report and consumer price index, are set to be released this week, which could influence the Fed's rate decisions, with markets pricing in the first rate cut potentially in June.
- Stock Movements: Eli Lilly shares rose 2.1% in premarket trading, while Hims & Hers dropped 14% after canceling a weight-loss pill launch due to FDA legal threats, highlighting market sensitivity to regulatory risks.
See More
Hims & Hers Shares Drop 15%: The Impact of Losing the Novo Wegovy Competition.
- Stock Decline: Hims & Hers Health's stock experienced a significant drop on Monday.
- Regulatory Scrutiny: The decline followed the company's decision to abandon plans for a generic version of the Wegovy weight-loss pill due to potential investigations by U.S. regulators.
See More
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Innovent and Eli Lilly Strengthen Collaboration for Innovative Therapies
- Strategic Collaboration: Innovent Biologics (IVBXF, 1801.HK) has announced its seventh strategic partnership with Eli Lilly, further solidifying their long-standing relationship and commitment to developing innovative therapies globally.
- Unique Development Model: This collaboration introduces a unique model designed to accelerate the global development of Innovent's pipeline, with Innovent leveraging its robust antibody technology platforms and efficient clinical execution capabilities to lead development from concept through Phase 2 clinical trials in China.
- Significant Financial Upside: Under the agreement, Innovent will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in development, regulatory, and commercial milestone payments, highlighting the potential financial benefits of this partnership.
- Global Market Rights: Eli Lilly will gain exclusive rights to develop and commercialize these programs globally outside of Greater China, while Innovent retains commercialization rights within Greater China, ensuring maximized interests for both parties in their respective markets.
See More
Eli Lilly Reports Strong Q4 Results Driven by Weight-Loss Drugs
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs generated $7.4 billion in Q4 sales, a 110% increase, while Zepbound's revenue surged from $1.9 billion to $4.3 billion, indicating strong market demand and product acceptance.
- Overall Performance Exceeds Expectations: The company reported a 43% increase in total revenue to $19.29 billion for Q4, with adjusted earnings per share (EPS) jumping 42% to $7.54, significantly surpassing analyst expectations of $6.67, reflecting the company's competitive edge and profitability.
- Optimistic Future Outlook: Eli Lilly projects 2026 revenue between $80 billion and $83 billion, representing a 25% growth at the midpoint, and forecasts adjusted EPS ranging from $33.50 to $35, demonstrating confidence in future market demand.
- Huge Potential for New Drug: The upcoming oral GLP-1 drug orforglipron is expected to gain approval in Q2, and its convenient administration method positions Eli Lilly to further expand its market share in the GLP-1 drug sector, reinforcing the company's leadership in weight-loss medications.
See More
Novo Nordisk Sues Hims Over Patent Infringement
- Escalating Legal Action: Novo Nordisk has filed a lawsuit seeking a permanent ban on Hims from selling compounded drugs that infringe its patents while also pursuing damages, demonstrating its commitment to defending its interests in the rapidly growing obesity drug market.
- Intensified Market Competition: Hims planned to offer its newly launched obesity pill at $49 per month, significantly lower than Novo's Wegovy, but has decided to halt sales after facing scrutiny from regulators and legal threats from the Danish drugmaker.
- Patient Safety Concerns: Novo accused Hims of deceiving patients by marketing unapproved drugs that lack FDA verification, highlighting the critical importance of regulatory standards to ensure drug safety and efficacy.
- FDA Investigation: The FDA has announced plans to take legal action against Hims, including restricting access to drug ingredients and referring the company to the Department of Justice for potential violations, further complicating Hims' legal challenges.
See More
Wall Street Futures Steady as Investors Await Economic Data
- Tech Stock Decline: Concerns over AI have led to a decline in tech stocks over the past week, putting pressure on the market as investors await crucial economic data and hints from the Federal Reserve regarding potential rate cuts.
- Dow Jones Performance: The Dow Jones closed above 50,000 points for the first time on Friday, posting significant weekly gains, indicating a rotation of funds into other sectors and boosting investor confidence.
- Economic Data Focus: Key economic releases, including the nonfarm payrolls report and consumer price index, are set to be released this week, which could influence the Fed's rate decisions, with markets pricing in the first rate cut potentially in June.
- Stock Movements: Eli Lilly shares rose 2.1% in premarket trading, while Hims & Hers dropped 14% after canceling a weight-loss pill launch due to FDA legal threats, highlighting market sensitivity to regulatory risks.
See More
Hims & Hers Shares Drop 15%: The Impact of Losing the Novo Wegovy Competition.
- Stock Decline: Hims & Hers Health's stock experienced a significant drop on Monday.
- Regulatory Scrutiny: The decline followed the company's decision to abandon plans for a generic version of the Wegovy weight-loss pill due to potential investigations by U.S. regulators.
See More
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Innovent and Eli Lilly Strengthen Collaboration for Innovative Therapies
- Strategic Collaboration: Innovent Biologics (IVBXF, 1801.HK) has announced its seventh strategic partnership with Eli Lilly, further solidifying their long-standing relationship and commitment to developing innovative therapies globally.
- Unique Development Model: This collaboration introduces a unique model designed to accelerate the global development of Innovent's pipeline, with Innovent leveraging its robust antibody technology platforms and efficient clinical execution capabilities to lead development from concept through Phase 2 clinical trials in China.
- Significant Financial Upside: Under the agreement, Innovent will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in development, regulatory, and commercial milestone payments, highlighting the potential financial benefits of this partnership.
- Global Market Rights: Eli Lilly will gain exclusive rights to develop and commercialize these programs globally outside of Greater China, while Innovent retains commercialization rights within Greater China, ensuring maximized interests for both parties in their respective markets.
See More
